Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and...

Area of Science:

• Neuro-oncology
• Clinical trial design
• Brain metastases research

Background:

• Assessing neurocognitive function, neurological symptoms, functional independence, and quality of life is critical for brain metastases patients.
• Current clinical trials for brain metastases exhibit significant variability in endpoint inclusion and assessment methodologies.
• Methodological inconsistencies in evaluating functional independence and quality of life can impact the interpretation and acceptance of trial findings.

Purpose of the Study:

• To review clinical trials for brain metastases concerning measures of clinical benefit.
• To provide a framework for the design and conduct of future clinical trials in neuro-oncology.
• To address the variability in assessing key endpoints in brain metastases research.

Main Methods:

• Review of existing clinical trials involving patients with brain metastases.
• Analysis of methodologies used to assess clinical benefit, including neurocognitive function and quality of life.
• Development of a framework based on the Response Assessment in Neuro-Oncology (RANO) working group's collaborative efforts.

Main Results:

• Identified substantial variation in the assessment of crucial endpoints in brain metastases trials.
• Highlighted the importance of reliable and valid endpoint measures for study outcomes.
• Established the need for standardized approaches to improve trial design and interpretation.

Conclusions:

• Standardized and validated outcome measures are essential for robust clinical trials in brain metastases.
• The proposed framework aims to enhance the design and conduct of future neuro-oncology trials.
• Improving assessment methods will lead to more reliable data and better acceptance of findings in brain tumor research.